ID   K562/A02
AC   CVCL_0368
DR   MCCL; MCC:0000262
DR   ChEMBL-Cells; CHEMBL4295416
DR   ChEMBL-Targets; CHEMBL4296448
DR   PubChem_Cell_line; CVCL_0368
DR   Wikidata; Q54899401
RX   PubMed=7668104;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=7668104;
RA   Yang, Chun-Zheng
RA   Luan, Feng-Jun
RA   Xiong, Dong-Sheng
RA   Liu, Bin-Ren
RA   Xu, Yuan-Fu
RA   Gu, Kong-Shu
RT   "Multidrug resistance in leukemic cell line K562/A02 induced by
RT   doxorubicin.";
RL   Zhongguo Yao Li Xue Bao 16:333-337(1995).
//